By Chris Rombach, Vice President of Sales and Marketing, Asahi Kasei Bioprocess America
The oligonucleotide manufacturing industry is experiencing significant growth, with numerous pharmaceutical companies investing in the development of novel pharmaceutical products and therapies. Synthetic oligonucleotides have already been used extensively, resulting in the approval of several oligonucleotide drugs by the FDA, with many more in development. This industry is projected to see exponential growth, with approximately 10% of new drug approvals being oligonucleotide-based.
In 2022, the five major trends in the oligonucleotide manufacturing process include scaling up production to meet increasing demand, implementing sustainable practices to reduce waste and use environmentally friendly materials, improving machinery for enhanced efficiency and easier scaling, embracing digitalization and automation for streamlined processes and data analysis, and striving for ideal synthesis by overcoming challenges in the synthesizing process.
Manufacturers are focused on modernizing facilities, optimizing machinery, and innovating more efficient synthetic processes to scale up production. Sustainability initiatives aim to minimize waste and use greener materials, while improved machinery enhances efficiency and maintenance. Digitalization enables real-time data analysis and process optimization. The ultimate goal is to achieve higher coupling efficiency and overcome challenges in oligo manufacturing.
Overall, the oligonucleotide manufacturing industry is rapidly evolving, driven by the need for eco-efficiency, scalability, and technological advancements.